Bill Meury, Incyte president and CEO, joins 'Fast Money' to talk potential M&A, its growth trajectory, its product pipeline, ...

For the first time, a team of experts from the Technical University of Munich (TUM), RWTH Aachen University, and the German ...

Eikon Therapeutics, Inc. eyes IPO to fund EIK1001 oncology pipeline; early Phase 2 data show 60% response rate. Click for ...

IDH-mutant glioma, caused by abnormalities in a specific gene (IDH), is the most common malignant brain tumor among young ...

A recent study published in the medical journal Gut has revealed a novel cancer-promoting mechanism of Streptococcus ...

The decision to end the programme comes 18 months after Genmab's former partner for the acasunlimab, BioNTech, pulled out of ...

Scientists have developed a new treatment strategy that could one day save the lives of children affected by aggressive brain stem cancers.

Spanish scientists have identified groups of genes associated with a predisposition to the development of ductal ...

Cancer survival rates climbed significantly in recent decades. But federal funding cuts could threaten that progress, ...

The U.S. Food and Drug Administration (FDA) has granted fast track designation to Alessa Therapeutics for its lead product ...

The TellDx CTC iChip platform enables high-efficiency isolation of intact circulating tumor cells without reliance on cell size or epithelial markers. This unbiased approach is particularly well ...

Oncolytics also recently expanded its Scientific Advisory Board with globally recognized experts from Memorial Sloan Kettering Cancer Center and MD Anderson Cancer Center, positioning the company for ...